Expert Advice, Articles & Blogs XiFin EXCELLENCE
Scaling Mrd Testing: Build the Reimbursement Infrastructure for Growth

Scaling MRD Testing: Build the Reimbursement Infrastructure for Growth

October 21, 2026 |
6 min read

Minimal residual disease (MRD) testing continues to expand across precision oncology as advances in next-generation sequencing, circulating tumor DNA analysis, and tumor-informed assays broaden its potential applications in hematologic malignancies and solid tumors. MRD testing can provide clinicians with important information about treatment response, residual disease, and recurrence risk, supporting more informed clinical decision-making throughout the patient’s care journey.

As clinical adoption expands, reimbursement frameworks and operational processes must continue to evolve to support appropriate coverage, payment, and patient access. Scientific validity is only the starting point. For laboratories offering MRD assays, success depends as much on science as the operational discipline, reimbursement strategy, and market access readiness.

Clinical evidence, market access strategy, and payor engagement are essential to expanding MRD testing—but they are only part of the reimbursement equation. Once coverage pathways are established and testing volume begins to grow, laboratories face another challenge: operationalizing complex payor requirements at scale.

MRD Testing Presents a Unique Reimbursement Challenge

MRD assays are personalized and longitudinal, often repeated throughout a patient’s treatment course. That creates a level of payor scrutiny that single-event diagnostics rarely face.

Frequency and episode-of-care requirements are a prime example. Coverage and billing rules may differ based on whether the patient has active cancer, the clinical indication, assay methodology, and how the payor defines the testing service or episode of care. Some policies also establish specific frequency limitations or requirements related to prior testing. As a result, laboratories may need visibility into a patient’s testing history, prior molecular testing, and clinical status to determine whether subsequent testing meets applicable coverage and billing requirements. That level of longitudinal tracking can be difficult to operationalize within traditional laboratory workflows.

Denials are changing, too. Beyond straightforward non-covered service denials, laboratories performing MRD testing encounter:

  • Medical necessity denials
  • Frequency and duplicate-testing denials
  • Prior authorization issues
  • Requests for additional clinical documentation
  • Experimental or investigational determinations, even as clinical adoption and supporting evidence grow

A Patchwork of Payor Policies

Coverage criteria for the same MRD assay and indication can differ widely from one payor to the next, and even between plans within a payor. One may cover serial monitoring for a specific cancer type, while another calls it investigational. Frequency rules and prior authorization requirements also vary. As the clinical evidence base and professional guidelines continue to evolve, payor policies may not always keep pace.

Keeping up requires ongoing monitoring of policy changes across Medicare (including MolDX and other MACs jurisdictions) as well as commercial payors. Manual tracking doesn’t scale, especially for labs serving multiple oncology service lines nationally. The result is inconsistent adjudication and claim-by-claim policy review before submission.

Documentation Must Come First

Payors increasingly expect records that support medical necessity, such as pathology confirmation, treatment history, molecular profiling results, risk assessments, and a rationale for testing intervals. For repeat testing, they may also ask for historical timelines and an explanation of why another test is warranted.

Where applicable, front-end workflows should also validate patient eligibility, benefit requirements, prior authorization obligations, and payor-specific coverage criteria before claim submission. Connecting those requirements to the patient’s clinical documentation and testing history can help identify reimbursement risk earlier in the process.

Why It Matters:

The practical lesson is to establish documentation requirements upstream—before claim submission, rather than after a denial. That pulls revenue cycle teams closer to lab operations and provider support, and it becomes harder when patient records are scattered across sites and EHRs. Laboratories can strengthen pre-bill workflows by integrating policy validation, documentation intake, authorization management, and claim review before submission.

Coding and Appeals Need a More Strategic Approach

As new MRD assays enter the market and test-specific Proprietary Laboratory Analyses (PLA) codes become available, laboratories must evaluate the appropriate coding strategy and applicable payor requirements. Considerations may include use of a test-specific CPT® Proprietary Laboratory Analyses (PLA) code versus an unlisted molecular pathology code; registration in the DEX® Diagnostics Exchange Registry and applicable Z-Code® identifier requirements under the MolDX® program; and applicable National Correct Coding Initiative (NCCI) edits and payor billing guidance.1

Generic appeal templates may be insufficient for complex molecular, genetic, and MRD denials because successful appeals often require patient-, test-, indication-, and payor-specific clinical and policy support. Effective appeals defend more than the MRD assay itself. They also defend the timing, frequency, and clinical rationale for repeat testing. Evidence libraries, denial analytics, and automated patient- and payor-specific appeal generation help labs build that case efficiently.

Key Takeaway: Reimbursement Intelligence as a Differentiator

Laboratories that continuously monitor policy changes, identify denial trends, benchmark reimbursement performance, and maintain visibility into a patient’s testing history can respond more quickly to emerging reimbursement barriers. Those capabilities are increasingly important to translating scientific innovation and clinical adoption into sustainable reimbursement. Labs that spot friction early, adapt workflows quickly, and engage providers on documentation requirements upfront are likely to see fewer denials, less administrative burden, and stronger financial performance.

The Bottom Line

MRD testing is among the most promising areas of precision oncology, but its success will be determined by more than assay innovation. The labs that thrive will pair strong science with scalable reimbursement operations, from policy intelligence and pre-bill review to data-driven appeals.

Is your lab ready to scale MRD testing? Talk with a XiFin expert about building the reimbursement infrastructure to support it.


Frequently Asked Questions

Minimal residual disease testing is used to detect very low levels of cancer cells or cancer-derived material that may remain during or after treatment.
MRD testing is often personalized and repeated over time, while coverage, documentation, authorization, coding, and frequency requirements vary by payor and plan.
Laboratories should validate eligibility, benefits, authorization requirements, coverage criteria, coding, supporting documentation, and relevant testing history.
Laboratories can reduce avoidable denials by monitoring policy changes, capturing documentation up front, applying payor-specific pre-bill rules, and reviewing claim risk before submission.
The appropriate code depends on the assay, available code set, payor policy, registration requirements, and billing guidance. Laboratories should validate the applicable requirements for each test and payor.
Repeat testing may require records that explain the clinical indication, timing, prior results, treatment history, and rationale for another test.
Denial analytics can help laboratories identify recurring payor, policy, documentation, coding, and workflow issues and prioritize corrective action.

1CPT is a registered trademark of the American Medical Association. MolDX, DEX, and Z-Code are trademarks of Palmetto GBA, LLC.

LaboratoryMolecularOncologyPrior AuthorizationRevenue Cycle Management

Sign up for Blog Alerts